title: Adenovirus vectors as HIV-1 vaccines: where are we? What next?
authors: aDivision of AIDS, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland bDivision of Infectious Diseases/Department of Medicine and Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California cAIDS Healthcare Foundation, Los Angeles, California, USA.
authors: Marie Patricia
authors: MP
authors: DʼSouza
authors: Otto O
authors: OO
authors: Yang
mesh_terms: D016915:AIDS Vaccines / Q000235:genetics / Q000276:immunology*; D000256:Adenoviridae; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D002986:Clinical Trials as Topic; D005822:Genetic Vectors / Q000276:immunology*; D015483:HIV Antibodies / Q000097:blood; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D015658:HIV Infections / Q000235:genetics / Q000517:prevention & control*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans
chemical_list: D016915:AIDS Vaccines; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; C514793:gp120 protein, Human immunodeficiency virus 1